NCT00123968 - Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults | Biotech Hunter

Enrollment

326

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

HIV Infections

Interventions

BIOLOGICAL

VRC-HIVDNA016-00-VP

1x10\^11 per unit vaccine administered intramuscularly via Bioinjector

BIOLOGICAL

VRC-HIVADV014-00-VP

4 mg administered intramuscularly via injection

BIOLOGICAL

VRC-DILUENT013-DIL-VP

Administered intramuscularly via Bioinjector

BIOLOGICAL

VRC-HIVADV014-00-VP placebo

4 mg administered intramuscularly via injection

Trial Locations (3)

Kenya Med. Research Inst./Walter Reed Project, Clinical Research Centre, Off Hospital Road. Kericho, Kericho

National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) CRS, Mbeya

Makerere University Walter Reed Project (MUWRP), Kampala

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH